2B30.F XERIS BIOPH.HOL. DL-0001

Healthcare Biotechnology Frankfurt Exchange
13.95 EUR
Close of Nov 11, 2026
4.48 13.96
Market cap
EUR 2.55B
P/E
-
P/B
58.29x
ROE
-48.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 2B30.F undervalued?

Graham number

The Graham number of XERIS BIOPH.HOL. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

XERIS BIOPH.HOL. DL-0001 fundamental analysis

No fundamental analysis for XERIS BIOPH.HOL. DL-0001 yet.

XERIS BIOPH.HOL. DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About XERIS BIOPH.HOL. DL-0001

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhib…

Full company profile